Loading
Life sciences · Journal article
Acs Nano · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Redox-responsive prodrug nanodelivery systems hold immense promise in cancer therapy, offering advantages of improved pharmacokinetics, enhanced tumor selectivity, and increased safety. However, compared with standard therapeutic formulations, prodrug nanodelivery systems fail to yield superior antitumor efficacy at equivalent doses, attributable to inadequate drug activation and intratumoral accumulation. Herein, the three-in-one drug-release module, comprising an α-disulfide bond, an ethylene glycol moiety, and a short carbon chain, was covalently linked to paclitaxel (PTX) to construct three prodrug nanoassemblies (PSBA10 NPs, PSBA12 NPs, PSBA14 NPs). Notably, PSBA10 NPs, which possessed the shortest carbon chain, exhibited hypersensitive redox-responsive drug release and potentiated antitumor efficacy. Although PSBA10 NPs exhibited better safety than paclitaxel solution (Taxol) at equivalent doses, superior efficacy remained unattainable. Interestingly, a temporal-dose-regulated glutathione (GSH) gradient across the liver-blood-tumor axis increased the intratumoral accumulation of PSBA10 NPs by approximately 3-fold, resulting in pronounced antitumor efficacy superior to Taxol. This transient depletion of GSH in the liver and blood reduced the cleavage of disulfide bonds in the systemic circulation, enhancing tumor accumulation and selective activation of PSBA10 NPs. Our study highlighted a tumor treatment model based on the synergistic strategy of structural optimization and GSH gradient regulation across the liver-blood-tumor axis to boost the efficacy of chemotherapy.